Entera Bio Ltd
Officers & Directors
Entera Bio Ltd - Executives and Directors - Roger J. Garceau, Director - Haya Taitel, Director - Sean Ellis, Director - Miranda Toledano, Chief Executive Officer and Director - Gerald Lieberman, Director - Dana Yaacov-Garbeli, Chief Financial Officer - Ron Mayron, Director - Gerald M. Ostrov, Director - Yonatan Malca, Director ,
Entera Bio Ltd currently has 22 employees.
News about Entera Bio Ltd Key Personnel |
Introducing Dr. Rachel B Wagman: A Leading Clinical Advisor Joins Entera Bio s Scientific Advisory Board
JERUSALEM, May 15, 2024 - Entera Bio Ltd. (NASDAQ: ENTX), a pioneering company in the development of orally delivered peptides and small therapeutic proteins, has recently announced the appointment of Dr. Rachel B Wagman, MD, FACE, FACP, as their Key Clinical Advisor and a distinguished member of its Scientific Advisory Board. With over two decades of experience in metabolic bone disease and women s health research and drug development, Dr. Wagman s addition to Entera Bio s team promises to drive significant advancements in their mission to revolutionize oral drug delivery.
Dr. Wagman s remarkable...
|
Entera Bio Ltd., a frontrunner in the development of orally delivered peptides and therapeutic proteins, recently disclosed that it has been granted a 180-day extension by the Nasdaq Stock Market LLC to regain compliance with the minimum bid price requirement. This extension showcases the company s commitment to meeting the necessary criteria for continued listing on the Nasdaq Capital Market. Additionally, the article highlights Entera Bio s remarkable return on investment (ROI) in the third quarter of 2023, surpassing its average ROI. This article will delve into the facts surrounding these developments and assess their impact on the company.
1. Nasdaq Extension:
Entera Bio has rece...
|
Entera Bio Secures $6.6 Million in Private Placement, Extending Cash Runway through 2025
Jerusalem-based biopharmaceutical company, Entera Bio Ltd. (NASDAQ: ENTX), has successfully concluded a private placement offering on December 22, 2023, raising approximately $6.6 million in gross proceeds. The placement involved existing and new investors who purchased 7,916,879 units at a price of $0.835 per unit. This recent financing will significantly extend Entera s cash runway, ensuring the company s financial stability through 2025.
Entera Bio is recognized as a pioneer in the development of orally delivered peptides and therapeutic proteins. The company s innovative oral drug delivery technology has the ...
|
|
